Published: January 7, 2026 at 10:19 am
Nasdaq-listed Amgen has agreed to acquire Oxford-based Dark Blue Therapeutics in a deal valued at around £622 million.
The swoop is set to strengthen the US MedTech giant’s early-stage oncology pipeline and its focus on targeted protein degradation.
Private firm Dark Blue Therapeutics is currently developing first-in-class small molecule therapies designed to degrade disease-driving proteins.
Its lead investigational programme targets MLLT1 and MLLT3, proteins implicated in certain forms of acute myeloid leukemia (AML), an aggressive blood cancer with limited treatment options and high relapse rates.
Amgen, listed in the US, has a market cap of $177.8 billion.
It is one of the world’s largest MedTechs, with a portfolio spanning oncology, cardiovascular disease, inflammation and rare conditions.